Syndax Pharmaceuticals (SNDX) Cost of Revenue (2024 - 2026)

Syndax Pharmaceuticals' Cost of Revenue history runs 3 years deep, the most recent figure standing at $11.8 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 1238.53% year-over-year to $11.8 million; the TTM figure through Mar 2026 stood at $4.2 million (up 145.0% YoY), while the FY2025 annual figure was $7.0 million, up 743.83% from the prior year.
• Cost of Revenue for Q1 2026 stood at $11.8 million, up from -$17.2 million in the prior quarter.
• The five-year high for Cost of Revenue was $11.8 million in Q1 2026, with the low at -$17.2 million in Q4 2025.
• The 3-year median for Cost of Revenue is $1.1 million (2025), against an average of $983833.3.
• The sharpest annual moves came in 2025 and 2026: Cost of Revenue plunged 2184.26% in 2025, then soared 1238.53% in 2026.
• Syndax Pharmaceuticals' Cost of Revenue stood at $826000.0 in 2024, then slumped by 2184.26% to -$17.2 million in 2025, then soared by 168.81% to $11.8 million in 2026.
• Business Quant data shows SNDX's Cost of Revenue at $11.8 million in Q1 2026, -$17.2 million in Q4 2025, and $8.3 million in Q3 2025.